DK1161548T3 - Rekombinant proteinproduktion i en human celle under anvendelse af sekvenser, der koder for adenovirus E1-protein - Google Patents

Rekombinant proteinproduktion i en human celle under anvendelse af sekvenser, der koder for adenovirus E1-protein

Info

Publication number
DK1161548T3
DK1161548T3 DK00921175T DK00921175T DK1161548T3 DK 1161548 T3 DK1161548 T3 DK 1161548T3 DK 00921175 T DK00921175 T DK 00921175T DK 00921175 T DK00921175 T DK 00921175T DK 1161548 T3 DK1161548 T3 DK 1161548T3
Authority
DK
Denmark
Prior art keywords
human cell
protein
sequences encoding
encoding adenovirus
production
Prior art date
Application number
DK00921175T
Other languages
English (en)
Other versions
DK1161548T4 (da
Inventor
Govert Johan Schouten
Alphonsus Gerardus C Uytdehaag
Abraham Bout
Guus Hateboer
Karina Cornelia Verhulst
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26153302&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1161548(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of DK1161548T3 publication Critical patent/DK1161548T3/da
Publication of DK1161548T4 publication Critical patent/DK1161548T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK00921175.6T 1999-04-15 2000-04-17 Rekombinant proteinproduktion i en human celle under anvendelse af sekvenser, der koder for adenovirus E1-protein DK1161548T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99201176 1999-04-15
EP99204434 1999-12-21
PCT/NL2000/000247 WO2000063403A2 (en) 1999-04-15 2000-04-17 Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein

Publications (2)

Publication Number Publication Date
DK1161548T3 true DK1161548T3 (da) 2005-05-23
DK1161548T4 DK1161548T4 (da) 2010-03-01

Family

ID=26153302

Family Applications (3)

Application Number Title Priority Date Filing Date
DK00921175.6T DK1161548T4 (da) 1999-04-15 2000-04-17 Rekombinant proteinproduktion i en human celle under anvendelse af sekvenser, der koder for adenovirus E1-protein
DK05100732.6T DK1533380T3 (da) 1999-04-15 2000-04-17 Rekombinant proteinproduktion i en human celle indeholdende mindst ét E1-protein af adenovirus
DK09174441.7T DK2163640T3 (da) 1999-04-15 2000-04-17 Rekombinant proteinproduktion i en human celle indeholdende mindst ét E1-protein af adenovirus

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK05100732.6T DK1533380T3 (da) 1999-04-15 2000-04-17 Rekombinant proteinproduktion i en human celle indeholdende mindst ét E1-protein af adenovirus
DK09174441.7T DK2163640T3 (da) 1999-04-15 2000-04-17 Rekombinant proteinproduktion i en human celle indeholdende mindst ét E1-protein af adenovirus

Country Status (18)

Country Link
EP (3) EP1533380B1 (da)
JP (1) JP4210036B2 (da)
CN (1) CN100457914C (da)
AT (3) ATE536417T1 (da)
AU (1) AU772352B2 (da)
CA (1) CA2370477C (da)
CY (1) CY1109759T1 (da)
DE (2) DE60018171T3 (da)
DK (3) DK1161548T4 (da)
ES (3) ES2378272T3 (da)
HK (1) HK1048138B (da)
IL (2) IL145849A0 (da)
MX (1) MXPA01010360A (da)
NO (1) NO328951B1 (da)
NZ (1) NZ514951A (da)
PT (2) PT1161548E (da)
SI (2) SI1161548T2 (da)
WO (1) WO2000063403A2 (da)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
WO2003048197A1 (en) * 2001-12-07 2003-06-12 Crucell Holland B.V. Production and of viruses, viral isolates and vaccines
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7425437B2 (en) * 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
EP1256803A1 (en) 2001-05-07 2002-11-13 Crucell Holland B.V. Methods for the identification of antiviral compounds
AU2002224199A1 (en) * 2001-10-29 2003-06-23 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
EA008220B1 (ru) 2001-10-29 2007-04-27 Круселл Холланд Б.В. Композиция, включающая эритропоэтинподобные молекулы, и способы ее применения
ATE384785T1 (de) * 2001-12-07 2008-02-15 Crucell Holland Bv Herstellung von viren, virusisolaten, und impfstoffen
DK1456238T3 (da) * 2001-12-17 2008-08-18 Crucell Holland Bv Produktion af F(ab')2-fragmenter i pattedyrceller
KR100454016B1 (ko) * 2002-01-05 2004-10-26 한국과학기술원 항예정사 유전자로 형질전환되고 ｄｈｆｒ 유전자가결핍된 신규한 ｃｈｏ 세포주, 그의 제조 방법 및 상기형질전환된 ｃｈｏ 숙주 세포를 이용한 목적단백질의 생산방법
US7335490B2 (en) * 2002-01-09 2008-02-26 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure
CA2476166C (en) 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US8287864B2 (en) 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
KR101017732B1 (ko) 2002-03-01 2011-02-28 이뮤노메딕스, 인코오포레이티드 내재화 항-ｃｄ74 항체 및 그 이용방법
AU2002307635A1 (en) * 2002-04-19 2003-11-03 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
ES2524767T3 (es) 2002-06-14 2014-12-12 Immunomedics, Inc. Anticuerpo monoclonal humanizado HPAM4
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
KR101115797B1 (ko) 2002-08-01 2012-07-27 이뮤노메딕스, 인코오포레이티드 알파 태아 단백질 Ｉｍｍｕ31 항체 및 융합단백질, 및이들의 이용 방법
US7541440B2 (en) 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
US8524477B2 (en) 2002-10-29 2013-09-03 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
NZ542585A (en) 2003-05-09 2007-11-30 Crucell Holland Bv Cultures of PER.C6-immortalized cells and processes for culturing the same to increase product yields therefrom
DK1626992T3 (da) * 2003-05-23 2010-09-20 Crucell Holland Bv Produktion af rekombinant IgM i PER.C6-celler
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
NZ543635A (en) 2003-06-25 2008-05-30 Crucell Holland Bv Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
EP1508576A1 (en) * 2003-08-20 2005-02-23 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
CN1863918B (zh) 2003-10-02 2011-03-30 克鲁塞尔荷兰公司 用于重组腺病毒的包装细胞
WO2005059149A2 (en) * 2003-12-12 2005-06-30 Chromagenics B.V. Improved protein production
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
PL1720972T3 (pl) * 2004-03-05 2014-06-30 Dpx Holdings Bv Proces hodowli komórek poprzez ciągłą perfuzję i zmienny przepływ styczny
PL2314621T3 (pl) 2004-05-27 2014-08-29 Crucell Holland Bv Cząsteczki wiążące zdolne do neutralizowania wirusa wścieklizny i ich zastosowania
JP4852046B2 (ja) 2004-10-12 2012-01-11 クルセル ホランド ベー ヴェー 癌の治療及び検出に用いる結合分子
BRPI0517380A (pt) 2004-11-08 2008-10-07 Chromagenics Bv molécula de dna, cassete de expressão, célula hospedeira, e, métodos para gerar uma célula hospedeira que expressa um polipeptìdeo de interesse e para produzir um polipeptìdeo de interesse
SG159542A1 (en) 2004-11-11 2010-03-30 Crucell Holland Bv Compositions against sars-coronavirus and uses thereof
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
CA2608058C (en) 2005-05-12 2013-09-10 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
WO2008057634A2 (en) * 2006-10-26 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AU2006312148B2 (en) * 2005-11-07 2012-04-12 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
AR053416A1 (es) 2005-11-10 2007-05-09 Protech Pharma S A Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
US7642078B2 (en) 2005-12-28 2010-01-05 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
EP1996705B1 (en) 2006-03-20 2011-08-31 ChromaGenics B.V. Expression augmenting dna fragments, use thereof, and methods for finding thereof
AU2007235413B2 (en) 2006-04-05 2012-08-02 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
DK2027155T3 (da) 2006-06-06 2016-05-09 Crucell Holland Bv Humane bindingsmolekyler med dræberaktivitet mod stafylokokker og anvendelser deraf
US7960518B2 (en) 2006-06-06 2011-06-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
FI2343362T4 (fi) 2006-07-14 2024-07-04 Patheon Holdings I B V Parannettu menetelmä solujen viljelyä varten
CA2663388C (en) 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
SG10201607410TA (en) 2006-09-07 2016-10-28 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
JP2010512306A (ja) * 2006-10-27 2010-04-22 ザ ロックフェラー ユニバーシティー 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
EP3176263A1 (en) 2007-08-10 2017-06-07 Toto Ltd. Method of producing recombinant mammalian cells
CN101939330B (zh) * 2007-12-13 2014-06-04 霍夫曼-拉罗奇有限公司 新型风疹e1包膜蛋白变体及其在检测抗风疹抗体中的用途
US20120039939A1 (en) * 2008-04-11 2012-02-16 The Johns Hopkins University Compositions and methods for vaccine and virus production
JP2011517960A (ja) 2008-04-22 2011-06-23 ザ ロックフェラー ユニバーシティー 抗炎症化合物の識別方法
KR101639454B1 (ko) * 2008-07-15 2016-07-13 크루셀 홀란드 비.브이. Ｐｅｒ．ｃ6 세포의 배양에 대한 확장가능 방법 및 그 방법으로 생산된 산물
CN102159243B (zh) 2008-07-21 2015-08-19 免疫医疗公司 用于改良的治疗特征的抗体的结构变体
DK2421895T3 (da) 2009-04-23 2016-01-25 Crucell Holland Bv Rekombinant human alfa1-antitrypsin
KR101790354B1 (ko) 2009-05-11 2017-10-25 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 ｈ3ｎ2를 중화시킬 수 있는 인간 결합 분자 및 그것의 용도
JP4998814B2 (ja) 2009-10-01 2012-08-15 Ｔｏｔｏ株式会社 Ｄｎａ構築物およびそれを用いた組み換えｃｈｏ細胞の製造方法
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
EP2731967B1 (en) 2011-07-14 2016-10-12 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
ES2872081T3 (es) 2011-08-05 2021-11-02 Regeneron Pharma Ratones con cadena ligera universal humanizada
AU2012340501A1 (en) 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
CN102827273A (zh) * 2012-02-16 2012-12-19 张小莺 抗痘苗病毒IgY抗体的制备
MX360056B (es) 2012-03-08 2018-10-19 Janssen Vaccines & Prevention Bv Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos.
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
US9657290B2 (en) 2012-07-03 2017-05-23 The Board Of Trustees Of The Leland Stanford Junior University Scalable bio-element analysis
WO2014006217A1 (en) 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
BR112015006824A2 (pt) 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
CA2884388A1 (en) 2012-09-27 2014-04-03 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing hepatitis b viruses and uses thereof
AU2014255864B2 (en) 2013-04-15 2019-07-18 Janssen Vaccines & Prevention B.V. Human antibodies binding to RSV G protein
WO2014170258A1 (en) 2013-04-15 2014-10-23 Crucell Holland B.V. Human antibodies binding to rsv g proteins
WO2015000856A1 (de) 2013-07-01 2015-01-08 Charité - Universitätsmedizin Berlin Immortalisierte humane chorionzelllinie sowie verfahren zur immortalisierung humaner chorionzellen
CN104693308B (zh) * 2013-12-05 2020-08-04 同济大学 感受胞内pH变化的Smad5蛋白及其应用
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
CA2941030C (en) 2014-02-28 2025-05-13 Merus N.V. ANTIBODIES THAT BIND TO EGFR AND ERBB3
DK3805268T3 (da) 2014-02-28 2025-01-20 Merus Nv Antistof, der binder erbb-2 og erbb-3
AU2015230938C1 (en) 2014-03-21 2021-10-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
TWI743024B (zh) 2014-06-06 2021-10-21 美商健臻公司 灌注培養方法及其用途
US10174127B2 (en) 2015-02-05 2019-01-08 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza neuraminidase
CA2975655C (en) 2015-02-05 2023-09-19 Janssen Vaccines & Prevention B.V. Binding molecules directed against influenza hemagglutinin and uses thereof
CN114277081A (zh) 2015-02-22 2022-04-05 里兰斯坦福初级大学理事会 微筛选装置、方法和产品
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
WO2017010874A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
JP7296728B2 (ja) 2015-10-23 2023-06-23 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子
US10703803B2 (en) 2016-03-01 2020-07-07 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza B neuraminidase
CN110198786A (zh) 2016-11-14 2019-09-03 浩康生物系统公司 用于分选目标颗粒的方法和装置
CA3056517A1 (en) 2017-03-28 2018-10-04 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
JP7737220B2 (ja) 2017-03-31 2025-09-10 メルス ナムローゼ フェンノートシャップ ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体
CA3058290A1 (en) 2017-04-18 2018-10-25 Universite Libre De Bruxelles Biomarkers and targets for proliferative diseases
EP3625264B9 (en) 2017-05-17 2023-10-25 Merus N.V. Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
RS66708B9 (sr) 2017-08-09 2025-08-29 Merus Nv Antitela koja se vezuju za egfr i cmet
EP3693013A4 (en) 2017-10-06 2021-06-30 Ono Pharmaceutical Co., Ltd. BISPECIFIC ANTIBODY
AU2018380765A1 (en) 2017-12-04 2020-06-11 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
WO2019149798A1 (en) 2018-02-01 2019-08-08 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
TWI849895B (zh) 2018-02-09 2024-07-21 日商小野藥品工業股份有限公司 雙特異性抗體
JP7390729B2 (ja) 2018-03-23 2023-12-04 ユニヴェルシテ リブル ドゥ ブリュッセル Ｗｎｔシグナル伝達アゴニスト分子
TWI862565B (zh) 2019-04-04 2024-11-21 日商小野藥品工業股份有限公司 雙特異性抗體
JP6881658B2 (ja) 2019-07-05 2021-06-02 小野薬品工業株式会社 Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療
CA3149309A1 (en) 2019-07-30 2021-02-04 Ono Pharmaceutical Co., Ltd. Bispecific antibody
WO2021025140A1 (ja) 2019-08-08 2021-02-11 小野薬品工業株式会社 二重特異性タンパク質
CN117441021A (zh) * 2021-06-11 2024-01-23 孟山都技术有限公司 用于改变蛋白积聚的方法和组合物
WO2024043227A1 (ja) 2022-08-23 2024-02-29 小野薬品工業株式会社 二重特異性抗体
WO2026068859A1 (en) 2024-09-30 2026-04-02 Université Libre de Bruxelles Wnt signaling agonist molecules in the treatment of a bone-related disease or disorder

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2573436B1 (fr) * 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US4892737A (en) * 1988-09-22 1990-01-09 University Of Florida Composition and method for enhancing permeability of topical drugs
GB8900483D0 (en) * 1989-01-10 1989-03-08 Celltech Ltd Recombinant dna method
ES2100953T3 (es) * 1991-08-01 1997-07-01 Fond Nat Transfusion Sanguine Expresion en lineas linfoblastoides humanas no tumorales con un vector integrante.
CA2144040A1 (fr) * 1993-07-13 1995-01-26 Michel Perricaudet Vecteurs adenoviraux defectifs et utilisation en therapie genique
US5610043A (en) * 1994-04-28 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services Human prostatic cell lines immortalized by adenovirus 12-simian virus 40 (AD12/SV40) hybrid virus
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie

Also Published As

Publication number Publication date
SI1161548T1 (en) 2005-08-31
CN1360638A (zh) 2002-07-24
IL145849A (en) 2009-07-20
DE60018171T2 (de) 2005-12-29
AU4152000A (en) 2000-11-02
PT1161548E (pt) 2005-06-30
ES2335775T3 (es) 2010-04-05
CA2370477A1 (en) 2000-10-26
JP2002541854A (ja) 2002-12-10
NO20014977D0 (no) 2001-10-12
DE60043273D1 (de) 2009-12-17
DE60018171D1 (de) 2005-03-24
EP2163640A1 (en) 2010-03-17
WO2000063403A3 (en) 2001-02-15
EP1161548B2 (en) 2009-10-14
SI1161548T2 (sl) 2010-02-26
DK1161548T4 (da) 2010-03-01
PT1533380E (pt) 2010-02-09
NO20014977L (no) 2001-12-17
NZ514951A (en) 2004-02-27
DK1533380T3 (da) 2010-02-01
AU772352B2 (en) 2004-04-22
IL145849A0 (en) 2002-07-25
HK1048138A1 (zh) 2003-03-21
MXPA01010360A (es) 2004-04-05
ATE536417T1 (de) 2011-12-15
SI1533380T1 (sl) 2010-03-31
ATE289354T1 (de) 2005-03-15
DE60018171T3 (de) 2010-05-20
DK2163640T3 (da) 2012-03-05
CA2370477C (en) 2010-06-29
WO2000063403A2 (en) 2000-10-26
ATE447617T1 (de) 2009-11-15
CN100457914C (zh) 2009-02-04
HK1048138B (zh) 2009-06-12
EP1161548B1 (en) 2005-02-16
NO328951B1 (no) 2010-06-28
ES2237420T3 (es) 2005-08-01
EP1533380A3 (en) 2005-06-22
JP4210036B2 (ja) 2009-01-14
EP1533380A2 (en) 2005-05-25
EP1533380B1 (en) 2009-11-04
CY1109759T1 (el) 2014-09-10
EP2163640B1 (en) 2011-12-07
ES2378272T3 (es) 2012-04-10
ES2237420T5 (es) 2010-03-03
EP1161548A2 (en) 2001-12-12

Similar Documents

Publication Publication Date Title
DK1161548T4 (da) Rekombinant proteinproduktion i en human celle under anvendelse af sekvenser, der koder for adenovirus E1-protein
AR074032A1 (es) Polipeptidos de eritropoietina modificados y usos de los mismos.
ATE323770T1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
ATE533845T1 (de) Eukaryotische signalsequenzen zur polypeptid- expression und polypeptid-anzeigebibliotheken
EP1423510A4 (en) ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
IL196893A0 (en) Site specific incorporation of non-natural amino acids by vertebrate cells
MXPA03002971A (es) Receptores de hematopoyetina hpr1 y hpr2.
EP1589106A4 (en) ADIPONEKTIN RECEPTOR AND GENERATING ENCODER
CY1114526T1 (el) Κατασταλτικες πρωτεϊνες μιας πρωτεασης (protease) και χρησεις αυτων
ATE358725T1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
PT1025245E (pt) Criacao rapida de linhas celulares estaveis de mamifero produzindo elevados iiveis de proteinas recombinantes
DK1098972T3 (da) Protein med lighed med neuroendokrinspecifikt protein samt cDNA kodende derfor
ATE255634T1 (de) Rekombinantes humanes erythropoietin mit vorteilhaftem glykosylierungsmuster
BR9909918A (pt) Método para a liberação de um hormÈnio de crescimento ou citocina de proteìna, peptìdeo ou polipeptìdeo fisiologicamente ativos a um vertebrado não-humano
ATE277178T1 (de) C-typ lektine
ATE320485T1 (de) Mutierte furin polypeptide, welche verbesserte eigenschaften aufweisen
ATE386054T1 (de) Glycosylierte humane interferon alpha isoform
CY1108643T1 (el) Κυτταρικη σειρα και χρησεις της
DE602006014140D1 (de) Mit scytovirin der domäne 1 verwandte polypeptide
KR930008148A (ko) 변이 인간 프로우로키나아제
DE60026049D1 (de) POLYPEPTIDE MIT GLUCANOTRANSFERASE AKTIVITÄT UND DAFüR KODIERENDE NUKLEINSÄUREN
GEP20084464B (en) Mutated neublastin
RU2008150348A (ru) ЭКСПРЕССИОННАЯ ПЛАЗМИДНАЯ ДНК pCID-PROC, КОДИРУЮЩАЯ ПРОТЕИН С ЧЕЛОВЕКА, И КЛЕТОЧНАЯ ЛИНИЯ DG-CID-PROC-1, ПРОДУЦИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ПРОТЕИН С ЧЕЛОВЕКА
DE602004023493D1 (de) Neues screening-verfahren
DE602005024974D1 (de) Polypeptid mit einer Delta-5-Fettsäure-Desaturierungsaktivität, für das Polypeptid codierendes Polynukleotid und Verwendung davon.